Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (9)
Phase 2 trials (17)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (18)
- Shire
- Octapharma
- Grifols
- Novartis
- Baxalta
- Laboratoire français de Fractionnement et de Biotechnologies
- Nihon Pharmaceutical Co., Ltd
- National Center for Research Resources (NCRR)
- University Health Network, Toronto
- Ohio State University
- University of Vermont
- Mayo Clinic
- Columbia University
- University of Amsterdam
- University of Lyon
- Mitsubishi Tanabe
- Vita-Salute University of Milano. Italy
- ICON
Organization Involved with Phase 2 Indications (18)
- Zenyaku Kogyo Co., Ltd.
- UCB
- Sanofi
- Biogen
- Mallinckrodt
- National Cancer Institute (NCI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Washington
- Nagoya University
- Northwestern University
- Oregon Health and Science University
- Tufts University
- University of Kansas
- Stony Brook University
- MedDay Pharmaceuticals
- Japan Agency for Medical Research and Development
- Collins Medical Trust
- argenx
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (4)